We propose that along with established CSF AD biomarkers, CSF C3 and FH levels will significantly enhance the distinction of different AD stages in clinical practice and trial design, minimize bias in single clinician or consensusbased diagnostic mechanisms, and reduce the biochemical heterogeneity within the existing syndromic categories. Here, FH is linked to Alzheimer disease.